TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26053350

Group type: EXPERIMENTAL
Intervention: More Fun with Sisters and Brothers program (MFWSB)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 84
Study: 23413014

Group type: EXPERIMENTAL
Intervention: PCI with TAXUS Express paclitaxel‐eluting stents
Number of subjects: 1800

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1800
Study: 21332375

Group type: EXPERIMENTAL
Intervention: VR-graded exposure therapy (VR-GET)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 19
Study: 19178390

Group type: EXPERIMENTAL
Intervention: TTFC administered in the evening
Number of subjects: 32

Group type: COMPARATOR
Intervention: TTFC administered in the morning
Number of subjects: 32
Study: 17578973

Group type: EXPERIMENTAL
Intervention: Extended-release epidural morphine (EREM) 10 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional epidural morphine 4 mg
Number of subjects: 70
Study: 15190961

Group type: EXPERIMENTAL
Intervention: Dopamine infusion at 2, 4, and 6 microg x kg(‐1) x min(‐1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16
Study: 11464357

Group type: COMPARATOR
Intervention: 10 mL of 0.75% ropivacaine plus 0.5 mL of 0.9% NaCl (solution A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10 mL of 0.75% ropivacaine plus 0.0012 mEq of NaHCO(3) (solution B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10 mL of 0.75% ropivacaine (with adrenaline) plus 0.015 mEq of NaHCO(3) (solution C)
Number of subjects: 60
Study: 9542366

Group type: EXPERIMENTAL
Intervention: Tape recorded Western music
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 38
Study: 7804502

Group type: EXPERIMENTAL
Intervention: AIDS education programs
Number of subjects: 497

Group type: COMPARATOR
Intervention: Perceived serostatus or recent testing
Number of subjects: 497
Study: 3201506

Group type: EXPERIMENTAL
Intervention: Intraluminal shunting
Number of subjects: 118

Group type: COMPARATOR
Intervention: No shunting (Control)
Number of subjects: 118
Study: 31305114

Group type: EXPERIMENTAL
Intervention: AWARE intervention (n = 32)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Waitlist control (n = 31)
Number of subjects: 63
Study: 27724149

Group type: EXPERIMENTAL
Intervention: Independent Review Committee (IRC) assessment
Number of subjects: 447

Group type: COMPARATOR
Intervention: Unblinded investigators assessment
Number of subjects: 447
Study: 25808588

Group type: EXPERIMENTAL
Intervention: TNF-α inhibitors (adalimumab, infliximab, etanercept, certolizumab pegol, golimumab)
Number of subjects: 495
Study: 23422159

Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy
Number of subjects: 0
Study: 21990966

Group type: EXPERIMENTAL
Intervention: Self-testing plus confirmatory HTC (parallel testing with two rapid finger-prick blood tests)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Standard HTC alone
Number of subjects: 298

Group type: COMPARATOR
Intervention: No testing
Number of subjects: 298
Study: 18328151

Group type: EXPERIMENTAL
Intervention: Back school program (five-weekly sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Weekly medical visits (control group)
Number of subjects: 60
Study: 16691029

Group type: EXPERIMENTAL
Intervention: Fluvastatin XL, 80 mg, morning administration
Number of subjects: 236

Group type: COMPARATOR
Intervention: Fluvastatin XL, 80 mg, evening administration
Number of subjects: 236
Study: 14552534

Group type: EXPERIMENTAL
Intervention: Normal attention characteristics group
Number of subjects: 2

Group type: COMPARATOR
Intervention: Attention deficit group
Number of subjects: 2
Study: 11083178

Group type: EXPERIMENTAL
Intervention: SENIC index
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: NNIS index
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Residuals of SENIC index
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Residuals of NNIS index
Number of subjects: 196
Study: 8665116

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (1 mg norethindrone and 35 micrograms ethinyl oestradiol) for 21 days, n = 7
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo, n = 3
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Follicular phase
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Endurance test during follicular phase
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Endurance test during luteal phase
Number of subjects: 10
Study: 1387301

Group type: EXPERIMENTAL
Intervention: 250 mg oral tablet formulation 1
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 250 mg oral tablet formulation 2
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intravenous infusion of the lactobionate salt
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral dosing of clarithromycin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic analysis of clarithromycin
Number of subjects: 22
Study: 6486186

Group type: EXPERIMENTAL
Intervention: Verbal praise
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Edible reward
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Vibration
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nonreinforcement phases
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: High-MA groups
Number of subjects: 66
Study: 31053943

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Contralateral non-exudative AMD eyes (Control)
Number of subjects: 20
Study: 29284534

Group type: EXPERIMENTAL
Intervention: Perineural catheter (PNC) with continuous local anaesthetic infusion for the first 5 postoperative days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard postoperative analgesia
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Follow-up assessments at 2 and 6 months post-surgery
Number of subjects: 50
Study: 27044596

Group type: EXPERIMENTAL
Intervention: 100 mg caffeine
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo (corn starch)
Number of subjects: 180
Study: 24330343

Group type: EXPERIMENTAL
Intervention: 40 mg oxymorphone ER after a high-fat meal
Number of subjects: 30

Group type: COMPARATOR
Intervention: 40 mg oxymorphone ER after fasting
Number of subjects: 30
Study: 22269272

Group type: EXPERIMENTAL
Intervention: Biodegradable fixation systems (Inion CPS)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Titanium fixation systems (KLS Martin)
Number of subjects: 230
Study: 21117499

Group type: EXPERIMENTAL
Intervention: Test product Lipivim (200 mg fenofibrate)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference product (200 mg fenofibrate)
Number of subjects: 24
Study: 17212680

Group type: EXPERIMENTAL
Intervention: Diclofenac epolamine (DHEP) 65-mg sachet
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Diclofenac epolamine (DHEP)
Number of subjects: 155
Study: 15144464

Group type: EXPERIMENTAL
Intervention: Rofleponide palmitate 400 microg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Budesonide 128 microg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12351301

Group type: EXPERIMENTAL
Intervention: Blind intubation with a gum-elastic bougie (Group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Indirect laryngoscopy with a laryngeal mirror (Group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 9700984

Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8027290

Group type: EXPERIMENTAL
Intervention: 600 IU/day kallikrein
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups (kallikrein and placebo)
Number of subjects: 44
Study: 2604760

Group type: EXPERIMENTAL
Intervention: Walking on a treadmill for 60 min
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sitting in a chair for 60 min
Number of subjects: 23
Study: 781495

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg per day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Prindolol (10 mg three times per day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Prindolol (10 mg three times per day) + Hydrochlorothiazide (50 mg per day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (no treatment)
Number of subjects: 16
Study: 31331578

Group type: EXPERIMENTAL
Intervention: Massage with olive oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28575274

Group type: EXPERIMENTAL
Intervention: Darapladib
Number of subjects: 15828

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15828
Study: 26282657

Group type: EXPERIMENTAL
Intervention: Group-based behavioral intervention supplemented with telephone counseling and tailored newsletters
Number of subjects: 692

Group type: COMPARATOR
Intervention: Less intensive control intervention
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Group-based behavioral intervention
Number of subjects: 692
Study: 21845501

Group type: EXPERIMENTAL
Intervention: Treatment A (gpc training for oral reading and spelling, orthographic spelling strategy, RAP training, morphological strategies)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Treatment B (gpc training for oral reading and phonological awareness, continued step 2 training, orthographic spelling strategy training)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Treatment A (RAP training during step 3)
Number of subjects: 24
Study: 22123798

Group type: EXPERIMENTAL
Intervention: Internet-delivered intervention (quarterly educational modules, practice guidelines, monthly literature summaries, automated e-mail reminders) for 27 months
Number of subjects: 15847

Group type: COMPARATOR
Intervention: Control clinics (standard care)
Number of subjects: 15847

Group type: EXPERIMENTAL
Intervention: Internet-delivered intervention
Number of subjects: 15847

Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 15847
Study: 19090555

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17035947

Group type: EXPERIMENTAL
Intervention: Radiation therapy (a single dose of 18.4 Gy)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham radiation (Control)
Number of subjects: 25
Study: 12964797

Group type: EXPERIMENTAL
Intervention: ACE Surgical resorbable blast media (RBM) dental implant
Number of subjects: 348
Study: 10846695

Group type: EXPERIMENTAL
Intervention: 6 days of treatment with clarithromycin 500 mg, amoxicillin 1 g and omeprazole 20 mg, b.i.d.
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: 7 days of treatment with clarithromycin 500 mg, amoxicillin 1 g and omeprazole 20 mg, b.i.d.
Number of subjects: 223
Study: 9356566

Group type: EXPERIMENTAL
Intervention: Panic Disorder Severity Scale
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Panic Disorder Severity Scale (after short-term treatment)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Panic Disorder Severity Scale (individual items)
Number of subjects: 186
Study: 8259896

Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback (EMG-BF)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 192
Study: 3769163

Group type: COMPARATOR
Intervention: Amiodarone alone (group 1, 20 patients)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Amiodarone plus type IA agent (group 2, 17 patients)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Procainamide (administered during amiodarone therapy)
Number of subjects: 37
Study: 30746574

Group type: EXPERIMENTAL
Intervention: AutoLap™ system
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 30589027

Group type: EXPERIMENTAL
Intervention: Hypofractionated SIB-IMRT at 3.6 Gy/f (total of 72 Gy/20 fractions) combined with temozolomide (TMZ) at 75 mg/m2/day during radiotherapy and 150-200 mg/m2/day for 5 days every 28 days.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hypofractionated SIB-IMRT at 4 Gy/f (considered dose-limiting toxicity)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hypofractionated SIB-IMRT at 3.6 Gy/f (MTD)
Number of subjects: 16
Study: 26439785

Group type: EXPERIMENTAL
Intervention: CRE (5 g of CRE monohydrate, 4 times per day; n = 14)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CRE + CAF (CRE + 300 mg·d of CAF; n = 13)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CRE + COF (CRE + 8.9 g of COF, yielding 303 mg of CAF; n = 13)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (PLA; n = 14)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CRE + CAF
Number of subjects: 54
Study: 25317071

Group type: EXPERIMENTAL
Intervention: Resistance exercise with amino acid supplementation (RT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Amino acid supplementation alone (EAA)
Number of subjects: 31
Study: 23229691

Group type: EXPERIMENTAL
Intervention: 1 mg intravitreal triamcinolone acetonide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4 mg intravitreal triamcinolone acetonide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (observation for SCORE-CRVO trial and grid photocoagulation for SCORE-BRVO trial)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care and triamcinolone treatments
Number of subjects: 0
Study: 19464461

Group type: COMPARATOR
Intervention: Sevoflurane-I group (1 minimum alveolar concentration of sevoflurane for 5 minutes)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sevoflurane-II group (2 cycles of 5 minutes of sevoflurane with 5-minute washout)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no further intervention)
Number of subjects: 30
Study: 17975455

Group type: EXPERIMENTAL
Intervention: Stroke rehabilitation interventions
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Multicomponent assessment
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: ICF Participation assessment
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Overall assessment of outcomes
Number of subjects: 491
Study: 15602501

Group type: EXPERIMENTAL
Intervention: 10 mg oral D‐amphetamine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 20 mg oral D‐amphetamine
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 11948270

Group type: EXPERIMENTAL
Intervention: Long-chain n-3 fatty acids (highest quartiles)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Lowest quartile of long-chain n-3 fatty acids
Number of subjects: 278
Study: 9802935

Group type: EXPERIMENTAL
Intervention: IMPH-350
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ig-Therasorb
Number of subjects: 20
Study: 7663009

Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Erythropoietin + alpha-interferon
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: alpha-interferon
Number of subjects: 31
Study: 2570958

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 101

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 101
Study: 58651

Group type: EXPERIMENTAL
Intervention: Horse antihuman thymocyte globulin (HAHTG) combined with prednisone and azathioprine (lmuran)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no HAHTG)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: HAHTG group
Number of subjects: 50
Study: 30463070

Group type: EXPERIMENTAL
Intervention: 6-month multicomponent exercise program
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Baseline myostatin levels
Number of subjects: 112
Study: 27749731

Group type: EXPERIMENTAL
Intervention: Traditional Resistance Training (TD)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pyramidal Resistance Training (PR)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 25
Study: 26138180

Group type: EXPERIMENTAL
Intervention: Resolute Zotarolimus Eluting Stent (R-ZES)
Number of subjects: 100
Study: 23318559

Group type: EXPERIMENTAL
Intervention: Choline supplementation (twice normal dietary levels)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 100
Study: 21113584

Group type: EXPERIMENTAL
Intervention: Exercise-training group (ET)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 60
Study: 18681892

Group type: EXPERIMENTAL
Intervention: Standard triple eradication therapy + Saccharomyces boulardii (250 mg b.i.d. for 4 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard triple eradication therapy (omeprazole/esomeprazole, amoxicillin and clarithromycin)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Standard triple eradication therapy + Saccharomyces boulardii
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard triple eradication therapy
Number of subjects: 90
Study: 16626572

Group type: EXPERIMENTAL
Intervention: Intracoronary autologous bone marrow mononuclear cells transplantation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard drug therapy and percutaneous coronary intervention (PCI)
Number of subjects: 35
Study: 14716843

Group type: EXPERIMENTAL
Intervention: Zhaoyangwan (ZYW)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Interferon (Control)
Number of subjects: 50
Study: 11696746

Group type: EXPERIMENTAL
Intervention: Ambulatory urodynamics
Number of subjects: 106

Group type: COMPARATOR
Intervention: Video cystometry
Number of subjects: 106
Study: 9477031

Group type: EXPERIMENTAL
Intervention: Cognitive approach treatment (n = 9)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Relaxation component treatment (n = 12)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study: 8203876

Group type: EXPERIMENTAL
Intervention: Slow stroke effleurage back rub
Number of subjects: 32

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 32
Study: 3299568

Group type: EXPERIMENTAL
Intervention: Ambroxol (10 mg/kg, i.v. twice daily for 7 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 29464846

Group type: EXPERIMENTAL
Intervention: DCB with ELCA
Number of subjects: 168

Group type: COMPARATOR
Intervention: Stent with ELCA
Number of subjects: 168

Group type: COMPARATOR
Intervention: Stent without ELCA
Number of subjects: 168
Study: 27470605

Group type: EXPERIMENTAL
Intervention: Age 10-17 years
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Overweight (>1 standard deviation)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Event-free survival
Number of subjects: 318

Group type: COMPARATOR
Intervention: Children aged 10-17 years
Number of subjects: 318

Group type: COMPARATOR
Intervention: Infants
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Overweight children aged 10-17 years
Number of subjects: 318
Study: 25711667

Group type: EXPERIMENTAL
Intervention: VO2max
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: HRR
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: HRmax
Number of subjects: 52
Study: 23291937

Group type: EXPERIMENTAL
Intervention: Individually tailored educational web pages addressing specific vaccine concerns
Number of subjects: 77

Group type: COMPARATOR
Intervention: Untailored educational web pages containing general information
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Individually tailored educational web pages
Number of subjects: 77

Group type: COMPARATOR
Intervention: Untailored educational web pages
Number of subjects: 77
Study: 20701112

Group type: EXPERIMENTAL
Intervention: Technologies adopted for provision in outpatient care
Number of subjects: 36

Group type: COMPARATOR
Intervention: Technologies excluded from provision
Number of subjects: 36

Group type: COMPARATOR
Intervention: Technologies suspended for assessment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Negative decisions based on evidence
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Positive decisions lacking RCT evidence
Number of subjects: 36
Study: 17997313

Group type: EXPERIMENTAL
Intervention: Barbiturate coma
Number of subjects: 12
Study: 16173858

Group type: EXPERIMENTAL
Intervention: Responsive parenting intervention
Number of subjects: 264

Group type: COMPARATOR
Intervention: Developmental information (Control)
Number of subjects: 264
Study: 14557454

Group type: EXPERIMENTAL
Intervention: GHRH antagonist infusion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 11
Study: 10805184

Group type: EXPERIMENTAL
Intervention: albendazole therapy
Number of subjects: 500

Group type: COMPARATOR
Intervention: untreated children
Number of subjects: 500
Study: 8927671

Group type: EXPERIMENTAL
Intervention: 20 mg fluoxetine daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 60 mg fluoxetine weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1830488

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (CO2 laser)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Classic cholecystectomy
Number of subjects: 12
Study: 7104182

Group type: EXPERIMENTAL
Intervention: Indomethacin retard 75 mg twice daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Indomethacin capsules 50 mg three times daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg suppository at night with 50 mg by mouth each morning
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Indomethacin retard therapy
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Conventional oral therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 15